2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1577 Trial in progress: A randomized phase II study comparing cytarabine + daunorubicin (7+3) vs (Daunorubicin and Cytarabine) liposome, cytarabine + daunorubicin + venetoclax, azacitidine + venetoclax, and (Daunorubicin and Cytarabine) liposome + venetoclax in patients aged 59 or younger who are considered high-risk acute myeloid leukemia as determined by myelomatch; A myelomatch substudy - MM1YA-S01

Paul J. Shami, MD, Megan Othus, PhD2, Tara L. Lin, MD3, Guillaume Richard-Carpentier Sr, MD4, Jan Cerny, MD, PhD5, Daniel Reed, MD6, Kristen O'Dwyer, MD7, Razan Mohty, MD8, Rita Assi, MD9, Ehab Atallah, MD10, Eric Stephen Winer, MD11, Brent Wood, MD, PhD12, Min Fang, MD, PhD, FACMG13, Cecilia CS Yeung, MD, Professor Pathology14, Jerald Radich, MD15, Shahanawaz Jiwani, MBBS, PhD16, Steven Gore, MD17, Lyndsay Harris, MD18, Richard F. Little, MD19, Harry Erba, MD, PhD20
1 Huntsman Cancer Institute, Salt Lake City, Utah, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
3 University of Kansas Medical Center, Kansas City, Kansas, United States
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
6 UVA Cancer Center, Charlottesville, Virginia, United States
7 University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
8 University of Alabama at Birmingham, Birmingham, Alabama, United States
9 Indiana University, Indianapolis, Indiana, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Children's Hospital Los Angeles, Los Angeles, California, United States
13 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
14 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
15 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
16 Frederick National Laboratory for Cancer Research/National Cancer Institute, Frederick, Maryland, United States
17 National Cancer Institute, Rockville, Maryland, United States
18 National Cancer Institute, Rockville, Maryland, United States
19 National Institutes of Health, Rockville, Maryland, United States
20 Duke Blood Cancer Center, Durham, North Carolina, United States
Background and Significance:
Acute Myeloid Leukemia (AML) comprises a heterogeneous group of myeloid neoplasms. Outcomes vary based on prognostic factors that rely on molecular and cytogenetic parameters as well as the presence of an antecedent hematologic disorder. Outcomes are particularly poor for patients who fall into the high-risk (adverse) category and for patients who are 60 years or older. High-risk patients are generally treated with stem cell transplant (SCT) when feasible after remission induction. The presence of minimal residual or measurable residual disease (MRD) at the end of induction negatively affects outcomes, including among patients who undergo SCT. The current standard induction regimen of cytarabine with an anthracycline (7+3) has limited efficacy in the high-risk population. The need for more efficacious induction regimens for high-risk patients is therefore evident.
AML patients 59 years or younger who have high-risk disease are frequently candidates for SCT because of good performance status and limited co-morbidities. Because MRD positivity is associated with inferior outcomes following SCT, induction regimens that increase rates of MRD-negative complete remission (MRDneg CR) may improve long-term outcomes in this population.
Study Design and Methods: 
myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice) is a National Cancer Institute–led precision medicine platform trial that uses rapid genomic profiling to match patients with newly diagnosed AML or myelodysplastic syndrome (MDS) to biomarker-driven treatment substudies. Subjects are enrolled onto the myeloMATCH Master Screening and Reassessment Protocol (NCT05564390) and are then assigned to study number MMY1A-S01 (NCT05554406) based on the results of cytogenetics and NGS.  
 
Patients must be ages 18-59 years of age with newly diagnosed, untreated AML and be classified as adverse risk AML per European Leukemia Net risk classification (2017). Participants with therapy-related AML, AML evolving from an antecedent hematologic disorder, or AML with myelodysplasia-related changes are eligible unless they received treatment for the preceding hematologic disorder. Participants with FLT3 mutations or t(9;22) are excluded.  Participants must have adequate cardiac, renal, and hepatic function.  
 
Eligible patients are randomized to a control arm of Cytarabine + Daunorubicin (7+3) or one of four experimental arms: (Daunorubicin and Cytarabine) Liposome; Cytarabine + Daunorubicin + Venetoclax; Azacitidine + Venetoclax; or (Daunorubicin and Cytarabine) Liposome + Venetoclax. Response assessment occurs after one cycle of induction (with or without re-induction as indicated by a mid-cycle bone marrow biopsy) for intensive chemotherapy arms.  For azacitidine plus venetoclax, the response assessment occurs after two cycles. 
 
The primary objective of this study is to compare MRDneg CR rates between each of the experimental regimens and Cytarabine + Daunorubicin (7+3). Secondary objectives are to estimate the frequency and severity of toxicities; to estimate rates of CR, CR with incomplete count recovery, event-free survival, time to relapse, relapse-free survival, and overall survival with each regimen; to describe and compare MRD negative CR rates by genomic subgroups within and across randomized arms. Randomization is stratified on two factors: TP53 status (TP53 mutated versus TP53 wild type) and age (18-39 versus 40-59). With 60 eligible participants per arm, each comparison of an experimental arm with the control arm has 89% power to detect a 20% absolute improvement to the MRDneg CR rates between the control arm and the experimental arms. The maximum sample size will be 335 patients (60 eligible participants plus up to 7 [10%] ineligible participants per arm).
 
MM1YA-S01 is a multisite, pan-NCTN study activated on May 16, 2024, led by SWOG, and is enrolling participants at 223 sites in the United States and Canada. As of July 20, 2026, 80 of a planned 335 patients have been enrolled.
Paul J. Shami, MD: Geron - Other (including travel support); JSK Therapeutics - Current equity holder in private company; Geron - Honoraria; Abcuro, Syndax Pharmaceuticals Inc., Sumitomo, Cantex, JSK Therapeutics; Pfizer (research material) - Research Funding; JSK Therapeutics - Research Funding; Committee member of Acute Lymphoblastic Leukemia panel in the National Cancer Center Network - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); JSK Therapeutics - Membership on a Board/Advisory Committee; Geron - Membership on a Board/Advisory Committee; JSK Therapeutics - Current Employment